Johnson & Johnson (JNJ) : First Niagara Bank reduced its stake in Johnson & Johnson by 3.62% during the Q4 period. The investment management company now holds a total of 179,104 shares of Johnson & Johnson which is valued at $19,253,680 after selling 6,721 shares in Johnson & Johnson according to the most recent disclosure to the SEC.Johnson & Johnson makes up approximately 5.25% of First Niagara Bank’s portfolio.
Other Hedge Funds, Including , Guinness Atkinson Asset Management Inc reduced its stake in JNJ by selling 500 shares or 14.01% during the fourth quarter. The Hedge Fund company now holds 3,070 shares of JNJ which is valued at $330,025. Johnson & Johnson makes up approx 0.19% of Guinness Atkinson Asset Management Inc’s portfolio.Davidson Garrard Inc reduced its stake in JNJ by selling 824 shares or 1.6% during the fourth quarter. The Hedge Fund company now holds 50,648 shares of JNJ which is valued at $5,444,660. Johnson & Johnson makes up approx 1.34% of Davidson Garrard Inc’s portfolio.Holderness Investments Co boosted its stake in JNJ during the Q4 period, The investment management firm added 302 additional shares and now holds a total of 14,942 shares of Johnson & Johnson which is valued at $1,606,265. Johnson & Johnson makes up approx 1.56% of Holderness Investments Co’s portfolio.Wetherby Asset Management Inc boosted its stake in JNJ during the Q4 period, The investment management firm added 1,269 additional shares and now holds a total of 49,215 shares of Johnson & Johnson which is valued at $5,290,613. Johnson & Johnson makes up approx 1.28% of Wetherby Asset Management Inc’s portfolio.Profund Advisors reduced its stake in JNJ by selling 11,643 shares or 4.44% during the fourth quarter. The Hedge Fund company now holds 250,696 shares of JNJ which is valued at $26,949,820. Johnson & Johnson makes up approx 1.35% of Profund Advisors’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016. Company shares were Upgraded by Barclays on Dec 1, 2015 to ” Overweight”, Firm has raised the Price Target to $ 115 from a previous price target of $101 .
Johnson & Johnson opened for trading at $106.99 and hit $107.84 on the upside on Friday, eventually ending the session at $107.5, with a gain of 0.71% or 0.76 points. The heightened volatility saw the trading volume jump to 1,47,58,303 shares. Company has a market cap of $296,631 M.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.